Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells

Yuhko Suzuki, Tsutomu Yoshida, Guoqin Wang, Takumi Aoki, Takuji Katayama, Shunsuke Miyamoto, Koji Miyazaki, Keiichi Iwabuchi, Mikio Danbara, Meijin Nakayama, Ryouichi Horie, Hirokazu Nakamine, Yuichi Sato, Naoya Nakamura, Nozomi Niitsu

Departments of Hematology, Transfusion Medicine and Cell Transplantation, Pathology and Otorhinolaryngology, and Kitasato Clinical Research Center, Kitasato University School of Medicine, and Department of Molecular Diagnostics, Kitasato University School of Allied Health Sciences, Sagamihara, Division of Pathology and Immunology, Kansai University for Medical Science, Osaka, Department of Pathology, Tokai University School of Medicine, Isehara, and Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Japan

Abstract

Introduction: Aberrant expression of T-cell markers is occasionally observed in B-cell lymphomas. We conducted a retrospective study to establish its incidence and to determine its relationship with clinical features of patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods: We reviewed DLBCL patients diagnosed between January 2002 and April 2009. Patients fulfilled the following criteria: (1) age >18 years, (2) HIV negative, (3) B-cell lymphoma confirmed by restricted expression of surface immunoglobulin light chains by flow cytometry (FCM). Aberrant T-cell marker expression (ATCME) was defined as positivity for CD2, CD3, CD4, CD7, and/or CD8 on DLBCL cells by FCM. Phenotyping was also performed by immunohistochemistry (IHC). Patients were grouped according to positive or negative ATCME and their clinical features including survival were compared. Results: Of 150 patients, 11 (7.3%) showed ATCME; CD2 and CD7 were most often expressed. ATCME was less often detected and the signal was weaker using IHC. There were no statistically significant differences in clinical features between the two groups. Conclusions: FCM may be useful to detect ATCME in a small amount of lymphoma cells. The mechanism responsible for ATCME, and whether it contributes in any way to the pathogenesis of B-cell neoplastic transformation, requires clarification.

Key Words
Aberrant T-cell expression · B-cell lymphoma · Diffuse large B-cell lymphoma cells · Flow cytometry · Immunohistochemistry

Introduction

Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of large B lymphoid cells in which the size of the nucleus equals or exceeds that of a normal macrophage, being more than twice the size of a normal lymphocyte. DLBCL
cells have a diffuse growth pattern, with the disease constituting 25–30% of adult non-Hodgkin lymphomas (NHL) in Western countries [1] and 33% in Japan [2].

Aberrant expression of T-cell markers by flow cytometry (FCM) is occasionally found in routine practice. Aberrant T-cell marker expression (ATCME) has been reported in some B-cell lymphomas [3–7] based on the widespread use of FCM as an auxiliary method employed for the diagnosis of malignant lymphoma. The phenomenon is well known to occur in DLBCL together with chronic inflammation [3] such as in pyothorax-associated lymphoma [4, 5], and plasmablastic lymphoma [6, 7], both of which are often associated with Epstein-Barr virus (EBV) infection. It has been shown that EBV latent membrane protein-1 is responsible for the up- and down-regulation of a variety of cell surface or cytoplasmic molecules, including Bcl-2 [8–10]. This modulatory effect of EBV infection might conceivably also affect the expression of other T-cell-specific molecules.

In the present study, we examine ATCME in DLBCL by FCM in order to clarify its relationship with clinicopathological features, the potential involvement of EBV infection, and impact on prognosis. Additionally, we compare the results obtained by FCM and immunohistochemistry (IHC).

Patients and Methods

Patient Selection

We reviewed DLBCL patients newly diagnosed at the Kitasato University Hospital and satellite hospitals between January 2002 and April 2009 (a period of 88 months). Patients meeting the following inclusion criteria were enrolled in this retrospective cohort study: (1) diagnosis of DLBCL based on pathology and restricted expression or disappearance of immunoglobulin (Ig) light chain by FCM [11], (2) age >18 years, and (3) serologically HIV negative.

The following clinical and pathological factors recorded within 1 month of diagnosis were reviewed and analyzed: age, gender, iatrogenic complications due to immunosuppression, clinical stage, B symptoms, international prognostic index (IPI), expression of CD5 [12], FCM findings including T-cell aberrancy, and laboratory data, including white blood cell count, hemoglobin concentration, platelet count, and serum levels of lactate dehydrogenase, C-reactive protein, calcium, and soluble IL-2 receptor. Clinical response to the CHOP with or without rituximab was evaluated by CT, which was performed no later than 2 months after the completion of chemotherapy. According to the International Working Criteria [13], patients were characterized either as having a complete response (CR), unconfirmed CR, a partial response, stable disease, or progressive disease. Patients refractory to the first regimen were classified as having progressive disease, even when the scheduled course of the first regimen had not been completed. Relapse was also determined according to the International Working Criteria [13], and the occurrence and time of disease-related death was recorded. Survival was defined as the time from the date of diagnosis to the date of death or the end of follow-up. The Ethics Committee of the Kitasato University School of Medicine approved this study.

Pathological Analysis

Formalin-fixed, paraffin-embedded tissues were stained with hematoxylin-eosin. The histological subtypes were classified according to the criteria of the World Health Organization (4th edition, 2008) [14] by more than two experienced pathologists. IHC was performed using the following primary antibodies (Abs): CD3 (F7.2.38; Dako, Glostrup, Denmark), CD5 (4C7; Novocastra, Newcastle, UK), CD10 (56C6; Novocastra), CD20 (L26; Dako), Bcl-2 (PG-B6p; Dako), and Mum-1 (MUM1p; Dako). Germin center B-cell and non-germinal center B-cell types were determined according to Hans et al. [15].

DLBCL cells manifesting ATCME by FCM were also tested by IHC using Abs to CD2 (AB75), CD4 (4B12), CD7 (LP15), and CD8 (1A5; all Novocastra). If CD8 was positive by FCM, Abs to TIA-1 (GeneTex, Irvine, Calif., USA) and Granzyme B (11F1; Novocastra) were also used for IHC.

In situ hybridization for EBV-encoded small non-polyadenylated RNAs (EBERs; EBER-1; DAKO) was also performed according to the manufacturer’s instructions.

Flow Cytometry

We reviewed all enrolled patients’ FCM analyses from data consisting of scattergrams and histograms of lymphoma cells, without taking median fluorescence intensities into account. These data were obtained from the SRL Laboratory (Hino, Japan). Prior to FCM analysis, suspensions of biopsied samples in RPMI medium were stained using combinations of 2 or 3 monoclonal Abs (mAbs) directly conjugated to the fluorescent molecules isothiocyanate and phycoerythrin. Immunophenotypic analysis followed the FCM method reported previously [11]. Analyses were performed within 24 h after biopsy sampling. To identify the lymphoma cell and to eliminate dead cells, 7-amino-actinomycin D (7-ADD) staining was performed on samples obtained from January 2007 through the end of the study period. Before using 7-ADD, CD45 gating was used to detect blasts and lymphoma cells [17, 18]. Thus, CD45 and right angle light scatter were used to gate on blasts and lymphoma cells in three-color analysis.

The routinely used mAbs included CD45 (2D1; Becton Dickinson, BD, Bedford, Mass., USA), CD2 (T11; Beckman-Coulter, BC, Fullerton, Calif., USA), CD3 (CD3, BC), CD4 (T4; BC), CD5 (T1; BC), CD7 (3A1; BC), CD8 (T8; BC), CD10 (J5; BC), CD19 (88B; BC), CD20 (B-Ly1; Dako), CD23 (MMH6; Dako), CD25 (2A3; BD), CD11c (BU15; BC), CD16 (3G8; BC), CD30 (Ber-H2; BC), CD34 (581; BC), CD56 (N901; BC), IgM (G20-127; BD), CD38 (T16; BC), κ-chain (TB-28; BD), and λ-chain (1-155-2; BD).

For the 7-ADD method, mAbs to CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, CD25, CD30, CD34, CD38, CD45, and CD56, as well as IgM, κ-chain and λ-chain were used. Similar reagents were used for CD45 gating as follows: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD23, CD25, CD30, CD34, CD56, κ-chain and λ-chain.
ATCME was assigned when >30% of the lymphoma cells in a sample were positive for CD2, CD3, CD4, CD7, or CD8. CD5 was not regarded as an aberrant T-cell marker because CD5-positive B-cells, B-1 cells, are normally present and CD5-positive B-cell lymphomas are common [12, 19].

Statistics

Continuous variables are presented as medians (25th and 75th percentiles) and compared using the Mann-Whitney U test. Numerical variables are given as numbers (%). The relationships between ATCME and clinical and pathological parameters were assessed by Pearson’s χ² test or Fisher’s exact test, as appropriate.

Cumulative survival of the patients was estimated using the Kaplan-Meier method, and statistically significant differences between the groups were estimated by log-rank test. For Kaplan-Meier curves, we limited the data to a follow-up period of 60 months to avoid the number at risk being too small. Patients surviving >60 months are reported as 60 months, and events occurring after the follow-up period were censored. The 5-year cumulative survival probability was estimated using the life table method with the interval length set at 6 months.

Multivariate analysis was by the Cox proportional hazard regression model to estimate independent prognostic effects of T-cell aberrancy and each of the other clinicopathological parameters on survival, adjusting for confounding factors. Within the present study population, there were 56 DLBCL-related deaths, which allow a maximum of 6 variables to be included in the regression model. The conventional p value of 0.05 or less was used to determine the level of statistical significance. All reported p values are two sided. Analyses were performed independently at our clinical research center using SPSS version 17.0 software (SPSS, Chicago, Ill., USA).

Results

Patient Characteristics

The clinicopathological characteristics of the 150 eligible patients are summarized in table 1. Fifty-eight (38.7%) were women, aged from 21.0 to 86.0 years (median 67.0 years). There were 28 (18.6%) stage I, 31 (20.7%) stage II, 43 (28.7%) stage III, and 48 (32%) stage IV patients, and a total of 43 patients (28.7%) with extranodal involvement. Chemotherapy was given to 121 patients, of whom 29 (19.3%) received a CHOP or CHOP-like regimen (ChemoTX) and 92 (61.3%) received rituximab plus CHOP or a CHOP-like regimen.

Of the 150 DLBCLs, 11 (7.3%) showed ATCME by FCM. CD2, CD3, CD4, CD7, and CD8 were expressed in 4 (2.7%), 0 (0%), 1 (0.7%), 6 (4.0%), and 2 (1.3%) cases, respectively. Two cases expressed two T-cell antigens. One case with DLBCL having aberrant CD7 expression is shown in figure 1.

Assessment of ATCME by IHC and FCM

At least two experienced pathologists reviewed the IHC sections. ATCME detected by FCM could be confirmed in some, but not all, of the cases (table 3). EBERISH was also performed on the 11 cases with ATCME. Only a single case was found to be positive for EBER. Two DLBCL cases with ATCME are depicted in figure 2.

Discussion

To the best of our knowledge, this is the first study exploring ATCME in a large series of DLBCL cases. We found that CD2 and CD7 expression is relatively common, in agreement with several reports on B-cell NHL (B-NHL), e.g. studies on the expression of CD7 (5%) and CD2 (2%) reported by Inaba et al. [20, 21], CD2 and CD8

DOI: 10.1159/000348550

Suzuki et al.
Aberrant T-Cell Expression and DLBCL

Regarding CD2 expression, earlier studies found that a small proportion of mature B cells do express CD2 [25, 26] and that this molecule is expressed on a substantial percentage of thymic B cells (46% in the fetal thymus and 75% in the postnatal thymus). It can also be expressed by mature circulating peripheral blood B cells (CD19+ and CD20+) in normal donors [26]. The presence of CD2 on the cell surface is required to mediate cell adhesion and to facilitate antigen recognition in the absence of intracellular signaling. In the murine model, CD2+ B cells are functionally associated with B-cell differentiation. The human and murine CD2 genes show a high degree of homology in both 5′ and 3′-gene flanking regions, suggesting that they may be regulated in a similar fashion [26].

Regarding CD7 expression, it is known that cord blood CD34+, CD7+, CD10−, and CD19− cells can rapidly generate small numbers of CD19+ cells in culture. CD7 expression may characterize an intermediate stage between stem cells, erythroid cells, and pro-B cells in neonates, but may be more closely associated with natural killer lineage-restricted precursors in adult marrow [27]. Thus, normal mature B cells do not express CD7 at all.

Several types of B-cell lymphomas, such as DLBCL with chronic inflammation [3] and plasmablastic lymphoma [6, 7], often show ATCME. EBV is considered to contribute to this phenomenon. However, EBER was positive only in a single case in the patients studied here, indicating that EBV is not a major factor responsible for ATCME in our cases.

Fig. 1. FCM findings of ATCME in a DLBCL case which was confirmed as B-cell lymphoma by Ig light chain restriction. After excluding dead cells by 7-ADD staining, cells from lymph nodes were gated by SSC and FSC. Based on the light chain restriction, >85% of the gated cells were λ-chain positive, suggesting that they were the products of clonally proliferating B cells. They are CD19 and CD7 positive.
Table 1. Characteristics of DLBCL patients (n = 150) with T-cell aberrancy

<table>
<thead>
<tr>
<th>Patients</th>
<th>T-cell aberrancy</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>positive</td>
<td>negative</td>
</tr>
<tr>
<td>Age, years</td>
<td>67 (55.3, 74.8)</td>
<td>67 (59.0, 73.0)</td>
</tr>
<tr>
<td>Gender, male</td>
<td>8 (72.7)</td>
<td>84 (60.4)</td>
</tr>
<tr>
<td>Performance status, 2&lt;</td>
<td>3 (27.2)</td>
<td>46 (33.3)</td>
</tr>
<tr>
<td>Extranodal involvement</td>
<td>2 (18.2)</td>
<td>41 (29.5)</td>
</tr>
<tr>
<td>ISC, positive</td>
<td>3 (27.3)</td>
<td>27 (25)</td>
</tr>
<tr>
<td>Stage</td>
<td>2 (18.2)</td>
<td>14 (10.1)</td>
</tr>
<tr>
<td>B symptoms, positive</td>
<td>5 (45.5)</td>
<td>47 (33.8)</td>
</tr>
<tr>
<td>IPI</td>
<td>28</td>
<td>2 (18.2)</td>
</tr>
<tr>
<td>FCM findings</td>
<td>30</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>CD5 positive</td>
<td>150</td>
<td>11 (100)</td>
</tr>
<tr>
<td>CD19 positive</td>
<td>11</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>Hans's criteria</td>
<td>60</td>
<td>7 (63.6)</td>
</tr>
<tr>
<td>GCB</td>
<td>57</td>
<td>3 (27.3)</td>
</tr>
</tbody>
</table>

Continuous variables are presented as medians (25th, 75th percentiles) and compared using the Mann-Whitney U test. Numerical variables are given as n (%) and compared with the χ2 test or Fisher’s exact test. GCB = Germinal center B cell; ISC = immunosuppressive condition; LDH = lactate dehydrogenase.

Table 2. Patients with DLBCL treated with CHOP with or without rituximab (n = 121)

<table>
<thead>
<tr>
<th>Patients</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>HR 95% CI p</td>
<td>HR 95% CI p</td>
</tr>
<tr>
<td>Aberrant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>0.32 (0.04–2.32) 0.36</td>
<td>0.44 (0.06–3.32) 0.43</td>
</tr>
<tr>
<td>Age</td>
<td>1.00 (0.97–1.03) 0.89</td>
<td>0.98 (0.95–1.01) 0.98</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1.03 (0.51–2.09) 0.93</td>
<td>1.66 (0.76–3.62) 0.20</td>
</tr>
<tr>
<td>IPI</td>
<td>1.43 (2.72–47.96) 0.11</td>
<td>2.41 (1.54–3.78) &lt;0.0001</td>
</tr>
<tr>
<td>CD5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>1.87 (0.89–3.91) 0.10</td>
<td>2.04 (0.88–4.74) 0.09</td>
</tr>
<tr>
<td>CD20</td>
<td>1.47 (0.60–3.60) 0.13</td>
<td>0.71 (0.50–1.01) 0.05</td>
</tr>
</tbody>
</table>
The reasons for ATCME are unclear, especially for the cases which have no normal counterparts, like CD3, CD4, CD7 or CD8 B-lymphocyte positivity. There may be technical difficulties in the detection of at least some of these antigens. FCM findings in the present study were only occasionally confirmed by IHC. This is probably due to relatively low numbers of T-cell-related markers expressed on the surface of neoplastic B cells that can be visualized by the more sensitive FCM technique. Normal T cells were always stained in the IHC sections examined, demonstrating that detection of T-cell surface markers is not generally problematic.

The assessment of ATCME in B-NHL may be useful to monitor the neoplastic component for detecting minimum residual disease, small populations with bone marrow involvement, CNS involvement, and earlier relapse. FCM analyses are not always performed in daily medical practice. Therefore, we stress that monitoring ATCME in patients with B-NHL can be reliably performed only by FCM but not IHC.

In our study, ATCME did not appear to be related to any clinicopathological features or survival. In the literature, CD2 or CD7 expression is reported to be associated with extranodal involvement in B-NHL at diagnosis [20]. Carulli et al. [24] estimated the frequency of CD8-positive B-NHL to be 1.89%, similar to our finding (1.7%). They suggested that such B-NHLs are characterized by a more favorable outcome. Other studies have also indicated that CD8 co-expression is a marker for less aggressive disease in chronic lymphocytic leukemia/small lymphocytic lymphoma, but also an indicator of aggressive clinical behavior and involvement of the central nervous system in

**Table 3.** Association between FCM and IHC findings of T-cell-related molecules expressed in DLBCL

<table>
<thead>
<tr>
<th></th>
<th>FCM positive</th>
<th>IHC positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD2</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>CD3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CD4</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CD7</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>CD8</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>TIA-1</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Granzyme B</td>
<td></td>
<td>0</td>
</tr>
</tbody>
</table>

The assessment of ATCME in B-NHL may be useful to monitor the neoplastic component for detecting minimum residual disease, small populations with bone marrow involvement, CNS involvement, and earlier relapse. FCM analyses are not always performed in daily medical practice. Therefore, we stress that monitoring ATCME in patients with B-NHL can be reliably performed only by FCM but not IHC.
mantle-cell lymphoma [28, 29]. However, since the results of our analysis are based on limited patient numbers, further studies are required to determine the bona fide clinicopathological significance of CD8 expression in B-NHL. To the best of our knowledge, there are no other reports on the clinicopathological significance of ATCME in DLBCL in the literature to date.

In conclusion, we have documented ATCME in a small proportion of DLBCL patients and shown that EBV does not appear to be primarily involved in this phenomenon. ATCME had no statistically significant impact on the survival of these DLBCL patients. To monitor ATCME in these patients, it is important to employ FCM because the ability of IHC to detect ATCME was very poor. It is hoped that we will be able to elucidate the mechanism(s) involved in ATCME in DLBCL, which could contribute to developing the most suitable treatment modality. The accumulation of a larger set of clinicopathological and survival data in this rare type of lymphoma could reveal significant differences in the disease course, and treatment requirements only hinted at the trend towards poorer survival in the small cohort of 11 patients examined here.

Acknowledgments

We would like to thank our colleagues, especially D.V.M. Taira, Ms. Yamanaka in the Hematology Department, and Ms. Tsuruta in the Pathology Department. Additionally, we also thank Mr. Horigome at SRL for his detailed information on mAbs used in FCM.

References


236

Acta Haematol 2013;130:230–237
DOI: 10.1159/000348550

Suzuki et al.


